Payment overview · 2025
General Payments
$520.32
15 reported records · 13 companies
Healthcare provider profile · identity verified
Lori Shae Hopper, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MINERAL WELLS, TX · NPI 1396033619
Verified facts
What the public records show
CMS Open Payments records show Lori Shae Hopper, FNP received $520.32 in general payments during 2025 across 15 reported records.
Janssen Biotech, Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $135.15 | 26.0% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $98.04 | 18.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.43 | 10.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.28 | 8.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.79 | 6.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $26.86 | 5.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.23 | 4.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.36 | 4.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.25 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.24 | 3.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.69 | 3.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.18 | 2.9% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $14.82 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.32 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $135.15 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $135.15 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $98.04 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $42.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 121 |
| Liothyronine Sodium | Liothyronine Sodium | 309 | 87 |
| Gabapentin | Gabapentin | 217 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 208 | 74 |
| Lisinopril | Lisinopril | 192 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 52 |
| Metformin Hcl | Metformin Hcl | 165 | 50 |
| Ozempic | Semaglutide | 159 | 28 |
| Alprazolam | Alprazolam | 131 | 39 |
| Montelukast Sodium | Montelukast Sodium | 123 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 118 | 35 |
| Furosemide | Furosemide | 118 | 42 |
| Losartan Potassium | Losartan Potassium | 114 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 40 |
| Potassium Chloride | Potassium Chloride | 100 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 33 |
| Omeprazole | Omeprazole | 87 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 22 |
| Meloxicam | Meloxicam | 76 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 20 |
| Simvastatin | Simvastatin | 71 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 16 |
| Clonazepam | Clonazepam | 65 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 22 |
| Azithromycin | Azithromycin | 61 | 54 |
| Estradiol | Estradiol | 60 | 18 |
| Ondansetron Odt | Ondansetron | 54 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 43 |
| Trazodone Hcl | Trazodone Hcl | 49 | 15 |
| Allopurinol | Allopurinol | 47 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 18 |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Progesterone | Progesterone, Micronized | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 42 | 19 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 15 |
| Eliquis | Apixaban | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 23 |
| Carvedilol | Carvedilol | 36 | 12 |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Np Thyroid | Thyroid,pork | 32 | 15 |
| Famotidine | Famotidine | 31 | 13 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Armour Thyroid | Thyroid,pork | 29 | suppressed |
| Pregabalin | Pregabalin | 27 | 12 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Glipizide | Glipizide | 26 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 19 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.32 · 15 records | Janssen Biotech, Inc. | AIRSUPRA, AUSTEDO XR, Bimzelx, DUPIXENT, KRYSTEXXA, LEQVIO, Ocrevus Zunovo, Ozempic, QULIPTA, REXULTI, Rybelsus, SIMPONI ARIA, TREMFYA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error